You are here: Geisinger Medical
Laboratories > Test
Catalog
Geisinger Medical Laboratories Test Catalog
OMEGA-3 AND -6 FATTY ACIDS |
||
Geisinger Epic Procedure Code: LAB1319
Geisinger Epic ID: 53201
|
||
SPECIMEN COLLECTION |
||
Specimen type: |
Plasma (preferred) or serum | |
Preferred collection container: |
||
Alternate Collection Container: |
6 mL red-top (plain, non-serum separator) tube
|
|
Specimen required: |
2 mL plasma (preferred) or serum; minimum 0.6 mL. | |
Special notes: |
Do not collect in gel tube. | |
| SPECIMEN PROCESSING |
||
Specimen processing instructions: |
Centrifuge and aliquot. | |
Transport temperature: |
Room temperature. | |
Specimen stability: |
Room temperature: 7 days. Refrigerated: 14 days. Frozen: 35 days. | |
Rejection criteria: |
Gross hemolysis • Grossly icteric • Lipemia • Plasma not collected in EDTA tubes • Serum separator tubes (SST®) | |
TEST DETAILS |
||
Additional information: |
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by the U.S. Food and Drug Administration. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes. | |
CPT code(s): |
82542 | |
| Note: The billing party has sole responsibility for CPT coding. Any questions regarding coding should be directed to the payer being billed. The CPT codes provided by GML are based on AMA guidelines and are for informational purposes only. | ||
Methodology: |
Chromatography/Mass Spectrometry |
|
Synonyms: |
Quest test code 91001, Omega 3/6 FA
|
|
Clinical significance: |
Omega-3 and -6 Fatty Acids - 1. Baseline and monitoring of individuals with known CVD (acute and chronic) to determine Rx and compliance. 2. Identify patients with known CVD risk with low omega-3 levels who may be candidates for supplementation/therapy. 3. Monitor patients on omega-3 supplementation/therapy to determine efficacy of treatment. 4. Potential role in risk reduction for non-CVD outcomes-aged related macular degeneration, RA, cancer, etc. (early data). | |